Bot Chart, page-9778

I'd actually expect the price to climb higher this time around when closer to the new approval date, as the science has been confirmed by the FDA, so the market now isn't wondering 'IF' approval of the product will be granted, but when.

BOT have shared several announcements and analyst reports on their website. The latest analyst report is from Euroz Hartleys dated 27 Sep - immediately following the disappointing review news. Their price target for BOT remained at 31c and they cited forecasts as follows:


As somebody else on here recently pointed out, these were significantly reduced forecasts from their last analysis, which makes no sense, as nothing has changed, other than a start date. What somebody did suggest is that neither BOT nor EH wants insurers to be worried about just how much market penetration BOT may have with SOFRDA and how much that will cost them. Seems reasonable, but who knows.

But even with reduced forecasts, as you can see, they are anticipating sales exceeding $100m/pa within 2 years. This would seem to be based on a very modest market penetration of under 1%. If BOT in the US simply met the same numbers of Ecclock sales in Japan by Kaken, we will easily exceed that revenue target.

As for cash, management have previously said they have enough cash to get them to launch, but they will need more money to go further into sales and distribution. They made a point of saying that a CR wasn't the only option, but that debt was an option too. Perhaps they may be able to borrow some money on the strength of income from royalties coming from Japan - I'm not certain. If a CR was required, yeah, you'd hope it would be after approval and after a significant increase in the SP! That said, even better would be if following approval somebody considered that the green light of which to buy BOT!